The ~$12.65 trust value vs. $10.31 market price creates a clear arbitrage for public shareholders to redeem. With only ~$792K remaining in trust and controlling shareholders holding ~97% of shares, the extension is virtually guaranteed but the SPAC has minimal capital to pursue a deal. Monitor for any definitive business combination announcement or further debt restructuring.
Price Chart
Executive Summary
Chain Bridge I is seeking shareholder approval to extend its deadline to complete a business combination from November 15, 2026 to November 15, 2027. The SPAC's trust account has dwindled to approximately $792,065 from an initial $234.6 million due to massive redemptions across multiple prior extension votes. The controlling shareholder group (Fulton AC, CBG, CB Co-Investment) holds ~96.67% of outstanding shares and has committed to vote in favor, making approval virtually certain. Public shareholders have redemption rights at ~$12.65 per share, well above the $10.31 market price, creating an arbitrage opportunity.
Key Facts
- Seeking to extend business combination deadline from November 15, 2026 to November 15, 2027
- Trust account balance as of September 24, 2026 was approximately $792,065, down from $234.6 million at IPO
- Per-share trust value ~$12.65 vs. last closing price of $10.31 on September 24, 2026
- Controlling shareholders (Fulton AC, CBG, CB Co-Investment) hold ~96.67% of outstanding shares and will vote FOR
- Prior business combination agreement with Phytanix Bio was terminated on April 7, 2025
- Company has $1,250,000 C/M Note due November 15, 2026 and $1,023,235 Bridge Financing Note outstanding
- No cash compensation paid to officers or directors to date
- Class A shares trade on OTC market and are subject to penny stock rules
Financial Impact
Trust account has been depleted from $234.6 million to ~$792,065 due to cumulative redemptions of ~$243.5 million across multiple extension votes. Outstanding debt includes $1.25M C/M Note and $1.02M Bridge Note.
Risk Factors
- Trust account may be nearly fully redeemed, leaving insufficient funds to complete a business combination
- Company has significant debt ($1.25M C/M Note due Nov 15, 2026, $1.02M Bridge Note) relative to trust assets
- Penny stock classification limits liquidity and exchange listing options
- Failed Phytanix Bio deal and multiple prior extensions suggest difficulty finding a viable target
- If no deal by November 15, 2027, automatic liquidation with warrants expiring worthless
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001213900-26-106331 |
| Document: 0001213900-26-106331-index-headers.html | 0001213900-26-106331 |
| Document: 0001213900-26-106331-index.html | 0001213900-26-106331 |
| Document: 0001213900-26-106331.txt | 0001213900-26-106331 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers